Department of Otorhinolaryngology-Head and Neck Surgery.
Department of Internal Medicine, Chungbuk National University College of Medicine, Chungbuk National University Hospital, Cheongju, Korea.
Medicine (Baltimore). 2021 Jan 15;100(2):e24122. doi: 10.1097/MD.0000000000024122.
To assess the impact of intraoperative intravenous dexamethasone on the reduction of postoperative morbidity in children undergoing adenotonsillectomy.
A double blind randomized controlled trial conducted among children undergoing adenotonsillectomy at a tertiary hospital in Korea from November 2018 to June 2019. Children were randomly assigned to receive dexamethasone (0.5 mg/kg, maximum dose 24 mg) or placebo intravenously after induction of anesthesia. The primary endpoint was the reduction of postoperative pain and postoperative nausea and vomiting (PONV); secondary endpoints were adverse effects like postoperative hemorrhage.
The study included 105 children, and 67 were male. Their mean age was 6.2 ± 2.1 years. There was no significant difference between the groups in terms of demographic data or the operation time. The pain scores of the dexamethasone group were lower than those of the control group, but no significant difference was found (all P > .05). The average pain visual analog scale (VAS) during the study period (day 0-7) was 3.67 ± 1.59 and 4.40 ± 2.01 in the dexamethasone group and control group, respectively (P-value = .107). When we compared early pain VAS (day 0-2) and late pain VAS (day 5-7), the dexamethasone group showed significantly lower early mean VAS compared to the control group (4.55 ± 1.78 vs 5.40 ± 2.05, P-value = .046). The mean VAS for PONV was significantly lower in the dexamethasone group than in the control group (1.89 ± 2.22 vs 3.00 ± 2.37, P value = .044).
In children undergoing adenotonsillectomy, dexamethasone decreased the early postoperative pain and PONV without increasing postoperative hemorrhage.
评估术中静脉内给予地塞米松对行腺样体扁桃体切除术的儿童术后发病率降低的影响。
这是一项在韩国一家三级医院进行的随机双盲对照试验,纳入 2018 年 11 月至 2019 年 6 月期间行腺样体扁桃体切除术的儿童。儿童在麻醉诱导后随机接受地塞米松(0.5mg/kg,最大剂量 24mg)或安慰剂静脉内给药。主要终点为术后疼痛和术后恶心呕吐(PONV)减少;次要终点为术后出血等不良反应。
研究纳入 105 例儿童,其中 67 例为男性。他们的平均年龄为 6.2±2.1 岁。两组在人口统计学数据或手术时间方面无显著差异。地塞米松组的疼痛评分低于对照组,但无显著差异(均 P>.05)。研究期间(第 0-7 天)的平均疼痛视觉模拟量表(VAS)评分分别为地塞米松组 3.67±1.59 和对照组 4.40±2.01(P 值=.107)。当我们比较早期疼痛 VAS(第 0-2 天)和晚期疼痛 VAS(第 5-7 天)时,地塞米松组的早期平均 VAS 显著低于对照组(4.55±1.78 vs 5.40±2.05,P 值=.046)。地塞米松组的 PONV 平均 VAS 明显低于对照组(1.89±2.22 vs 3.00±2.37,P 值=.044)。
在行腺样体扁桃体切除术的儿童中,地塞米松可降低术后早期疼痛和 PONV,而不会增加术后出血。